Report for Q1 2025
Filed with SSE · · 12 pages · Chinese
Shanghai Xiao Fang Pharmaceutical Co., Ltd. on 6ix
Earlier from Shanghai Xiao Fang Pharmaceutical
- Announcement on the Initial Granting Results of the 2025 Restricted Stock Incentive Plan
- Announcement on Listing and Circulation of Restricted Shares in Offline Placement of Initial Public Offering
- Announcement on the Initial Granting of Restricted Stock to the Incentive Objects of the 2025 Restricted Stock Incentive Plan
- Board of Supervisors' Remarks on Verification Opinions on and Publicity of List of Incentive Objects under Restricted Stock Incentive Plan of 2025
- Announcement on the Notice on Convening the 1st Extraordinary General Meeting in 2025
Later from Shanghai Xiao Fang Pharmaceutical
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Implementation of Dividend Distribution for 2024
- Announcement on Completion of Industrial and Commercial Change Registration
- Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
- Announcement on Voluntary Disclosure of Cooperation with Shanghai Skin Disease Hospital to Develop Class 1.1 New Traditional Chinese Medicine Compound Platycladus Orientalis Tincture for the Treatment of Hair Loss
Follow Shanghai Xiao Fang Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai Xiao Fang Pharmaceutical